The aim of therapeutics target identification and validation research at The Kinghorn Cancer Centre is to take early stage scientific discoveries and guide them towards proof-of-concept or first-in-man trials.  This supports our strategic objective to ensure that scientific discoveries are translated into new treatments that address clinical needs.

Unfortunately cancer cells often rapidly adapt to attack by effective therapies in a process termed drug resistance.  Consequently we have a major program of research to understand why some tumours fail to respond or rapidly acquire resistance to specific therapies.  This is an integral component of the personalised medicine approach where therapy is targeted to those most likely to respond.

Find out more about our researchers’ research by clicking on their profiles listed on our Research Staff page.